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Introduction: Activation of diverse pathophysiologic processes that include thrombotic, inflammatory, and immune pathways contribute to 
plaque rupture and adverse outcomes in CAD. We hypothesized that an aggregate biomarker risk score comprised of C-reactive protein (CRP), fibrin 
degradation products (FDP), cytomegalovirus (CMV) antibody, and Heat Shock Protein 70 (HSP70) would improve future risk assessment of adverse 
events in subjects with risk factors for, or with established CAD.
Methods: 3,763 consecutive patients (60% with CAD; = 50% minimum stenosis in ≥1 artery) admitted for cardiac catheterization were enrolled 
in the Emory Biobank and followed for adverse cardiovascular outcomes over 2.5 years. Those with acute myocardial infarction (MI) and transplants 
were excluded. Serum biomarkers were measured using ELISA. Cox proportional hazard survival analyses and receiver operator statistics were 
performed with models adjusted for age, BMI, sex, race, smoking, diabetes, hypertension, and coronary severity score. Data were analyzed as 
continuous variables and with cut points.
Results: Preliminary analyses in a 1500 subject cohort revealed CRP, HSP70 and FDP significantly predicted outcome of death and MI. Definitive 
analyses were performed in 3550 subjects; hazard ratios (HRs) were calculated for two specific clinical situations: 1) subjects being evaluated for 
possible CAD; 2) those with angiographically documented CAD. In subgroup 2, HR for death and MI was: CRP ≥3.0 mg/L =1.48; HSP70 >0 =2.51; 
FDP ≥1.0 μg/ml =1.71 (p for each: <0.0001). For aggregate analyses: HR = 2.29 for 1 biomarker positive; 3.52 for 2 biomarkers; and 6.45 for 3 
biomarkers (p for each: <0.0001). Annualized risk of death and MI was 18% in those with 3 positive biomarkers (4% of subgroup) compared to 2% 
in those with no positive biomarkers (35% of subgroup). For subgroup 2, the C-Statistic of 0.64 for a model based on traditional risk factors was 
improved to 0.74 (p<0.0001) with addition of the 3 biomarkers. Results were similar for subgroup 1.
Conclusions: An aggregate score based on serum levels of CRP, FDP and HSP70 is a strong predictor of future risk of death and MI in patients at 
risk of CAD and those with known CAD.
